Investigation Report on China Gliclazide Market, 2010-2019
|発行||China Research and Intelligence||商品コード||334100|
|出版日||ページ情報||英文 30 Pages
|グリクラジドの中国市場 Investigation Report on China Gliclazide Market, 2010-2019|
|出版日: 2015年07月02日||ページ情報: 英文 30 Pages||
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.
First developed by Servier (France), gliclazide entered China in 1985. Gliclazide acts in a mild way and since it can inhibit platelet aggregation and thrombosis as well as lower blood viscosity, it both reduces blood glucose and prevents microangiopathy. Before Servier (France) developed gliclazide sustained-release tablet which should be given at a dose of 30 mg once daily in Nov. 2000 only gliclazide immediate-release tablet, a 80 mg formulation that should be taken in two divided doses daily, was available in the market.
Although over ten local enterprises got the approval to produce gliclazide, they all took up a small market share, among which Servier (Tianjin) Pharmaceutical Co., Ltd ranked first despite a share of less than 2% due to the support from Servier (France) that began to cooperate with it in 1987 to produce gliclazide sustained release tablet.
According to CRI's market survey, in 2014, Servier (France) and its subsidiary Servier (Tianjin) Pharmaceutical Co., Ltd took up a market share of about 96% for sales value in China while other companies like Tianjin Huajin Pharmaceutical Co., Ltd, Helioeast and Beijing Wansheng Pharmaceutical Co., Ltd shared the rest market share. The sales value of gliclazide was about CNY 137 million in 2014 and CAGR reached 12% during the period of 2005-2014.
The market size of gliclazide is expected to keep growing in the next few years in China.
Readers can get at least the following information through this report:
The author suggests the following groups of people purchase this report: